IAPs limit activation of RIP kinases by TNF receptor 1 during development
Maryline Moulin, Holly Anderton, Anne K Voss, Tim Thomas, Wendy Wei-Lynn Wong, Aleksandra Bankovacki, Rebecca Feltham, Diep Chau, Wendy D Cook, John Silke, David L Vaux
EMBO Journal | WILEY | Published : 2012
Awarded by NHMRC
This work was funded by a Centre grant from the Leukemia and Lymphoma Society, and NHMRC grants and fellowships 433063, 461221, 541901, 575512, 1003435, and was made possible through Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS. We thank Michelle Kelliher for providing Ripk1<SUP>+/-</SUP> mice; Vishva Dixit for the Ripk3<SUP>-/-</SUP> mice; Heinrich Korner for the Tnfr1<SUP>-/-</SUP> and Tnfr2<SUP>-/-</SUP> mice; Mark McKinlay for biotinylated and non-biotinylated Smac mimetic compounds (TetraLogic Pharmaceuticals). We thank CAH staff at Latrobe University, especially Jose Ramos, Samantha Kelly, and Melinda Boulton for mouse husbandry, and Frank Koentgen (Ozgene) for generating the cIap2<SUP>FRT/FRT</SUP>cIap1<SUP>lox/lox</SUP> mice.